ClinicalTrials.gg
RecruitingNCT07541534Updated May 28, 2026

A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of HLX316 in Advanced/Metastatic Solid Tumors, sponsored by Shanghai Henlius Biotech. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is an open-label, first-in-human Phase I clinical study to evaluate the safety, tolerability, PK characteristics, and preliminary antitumor activity of HLX316 in participants with advanced/metastatic solid tumors. The study will consist of 2 parts: a Phase Ia dose-escalation part and a Phase Ib dose-expansion part. Phase Ia and Phase Ib will focus on exploring the preliminary antitumor activity of HLX316 in participants with platinum-resistant ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

02

Conditions studied

  • Advanced/Metastatic Solid Tumors
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the contents, process and possible adverse reactions of the study before the study, sign the form, voluntarily participate in the study, and be able to complete the study according to the requirements of the study protocol;
  2. Aged ≥ 18 years at the time of signing ICF;
  3. Participants with or cytologically confirmed advanced or solid tumors who have failed at least one line of standard systemic therapy in the advanced or metastatic setting (participants who received or adjuvant therapy and experienced progressive disease or relapse within 6 months after completion of such therapy will be considered to have failed one line of standard therapy), or for whom no effective standard therapy is available, or who are intolerant of or refuse standard systemic therapy;
  4. At least 1 per v1.1 within 4 weeks prior to the first dose; for participants who have received prior radiotherapy, a previously irradiated lesion may be considered a target lesion if it is measurable per RECIST v1.1 and there is objective evidence of significant progression following radiotherapy; brain metastatic lesions may not serve as target lesions;
  5. performance status of 0 or 1 within 7 days prior to the first dose;
  6. Expected survival of more than 3 months;
  7. At least 28 days must have elapsed between the first dose of drug and any prior major surgical procedure, medical device treatment, local radiotherapy (except palliative radiotherapy for bone lesions), cytotoxic chemotherapy, immunotherapy, or biologic therapy; at least 14 days must have elapsed since prior small-molecule targeted therapy or hormonal therapy; at least 7 days must have elapsed since prior traditional Chinese medicine with antitumor indications or minor surgery; and any treatment-related AEs must have recovered to v6.0 Grade ≤ 1 (except alopecia);
  8. The participant agrees to provide specimen sufficient to meet testing requirements (from the most recent surgery or biopsy, preferably within 3 years) or agrees to undergo a fresh biopsy for tumor tissue collection (unless the investigator determines that the procedure would pose an unacceptable risk to the participant's safety), for assessment of tumor sialylation and protein expression including B7-H3; Note: Participants are required to provide a formalin-fixed, paraffin-embedded (FFPE) tumor sample (paraffin block or unstained sections, meeting quality control standards for testing) collected from a non-irradiated site at the time of or after the diagnosis of , from the most recent surgery or biopsy, along with the corresponding pathology report for the above specimen.
  9. Adequate organ function confirmed by laboratory assessments performed within 7 days prior to the first dose of study drug (without receipt of transfusions, granulocyte colony-stimulating factors, or thrombopoietic agents within 14 days prior to the first dose):

    Hematologic System (ANC) ≥ 1.0 × 109/L count (PLT) ≥ 75 × 109/L (Hb) ≥ 90 g/L Liver Function Total (TBIL) ≤ 1.5 × (ULN), unless a known genetic cause of elevated bilirubin is present (e.g., Gilbert's syndrome) (ALT) ≤ ULN; ≤ 2.5 × ULN for participants with hepatic metastases or hepatocellular carcinoma Aspartate aminotransferase (AST) ≤ ULN; ≤ 2.5 × ULN for participants with hepatic metastases or hepatocellular carcinoma Renal Function Creatinine (Cr) ≤ 1.5 × ULN; if > 1.5 × ULN, must be ≥ 40 mL/min (calculated using the Cockcroft-Gault formula) Coagulation Function (unless the participant is receiving anticoagulant therapy) (APTT) ≤ 1.5 × ULN Prothrombin time (PT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN

  10. Male and female participants of must agree to use at least 1 highly effective method of during the study and for at least 6 months after the last dose of investigational drug; female participants of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.
  11. The tumor type for participants with advanced solid tumors may be any of the following:

    • Platinum-resistant ovarian cancer
    • Other advanced/metastatic solid tumors with B7-H3 expression confirmed by IHC.
  12. Participants with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer must also meet all of the following criteria:

    • Histologically or pathologically confirmed epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer, with no evidence of non-epithelial carcinoma, borderline tumor, mucinous carcinoma (or seromucinous carcinoma with a predominant mucinous component), malignant Brenner tumor, or undifferentiated carcinoma.
    • Participants must have received at least 2 for metastatic ovarian cancer, including at least 1 platinum-based regimen, or must be intolerant to such standard treatments.
    • Must be platinum-resistant, defined as progressive disease confirmed by CA-125, clinical, or imaging assessment within 6 months after the last platinum-containing chemotherapy regimen.

Exclusion criteria

Exclusion Criteria:

  1. History of arterial thromboembolic events, stroke, or within the past 12 months.
  2. History of symptomatic chronic heart failure ( [NYHA] Class II-IV or [LVEF] \< 50%) or history of arrhythmia requiring treatment (including ≥ 450 ms in males or ≥ 470 ms in females) (QTc interval calculated using the Fridericia formula).
  3. History of myocardial infarction or unstable angina within 6 months prior to the first dose of HLX316.
  4. Evidence of active infection requiring intravenous antibiotic therapy during the screening period, or evidence of active infection requiring treatment within 7 days prior to the first dose of HLX316.
  5. Active uncontrolled bleeding or bleeding tendency within 7 days prior to HLX316 administration.
  6. Serious or non-healing wounds, fistulas, skin ulcers, or non-healing fractures within 7 days prior to HLX316 administration.
  7. The participant has previously participated in this study.
  8. The participant is currently participating in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up phase of an interventional study.
  9. Receipt of any other therapy within 3 weeks or 5 half-lives prior to HLX316 administration, whichever is shorter.
  10. Known infection with (HIV) (any HIV seropositivity or detectable human immunodeficiency virus type 1 ribonucleic acid [HIV RNA]).
  11. Active syphilis infection, defined as positive serological test result that has not been adequately treated.
  12. Active or infection. Participants with well-controlled hepatitis B virus/hepatitis C virus (HBV/HCV) infection may be eligible if the following criteria are met and after discussion with the Medical Monitor (MM):

    Hepatitis B:

    • Hepatitis B surface antigen (HBsAg)-positive (chronic HBV infection): participants are eligible if they are receiving antiviral therapy and hepatitis B virus deoxyribonucleic acid (HBV DNA) is controlled/undetectable.
    • HBsAg-negative and anti-hepatitis B core (HBc)-positive (resolved prior infection): eligible for enrollment. Prophylactic treatment should be considered and reactivation should be monitored.

    Hepatitis C

    • Prior HCV infection that has been successfully cured (ribonucleic acid [RNA] undetectable).
    • HCV Ab-positive but RNA-negative (spontaneous clearance).
  13. Participants with untreated central nervous system (CNS) epidural tumors or , or untreated . Known , or uncontrolled or symptomatic central nervous system (CNS) metastases, manifesting as clinical symptoms, cerebral edema, spinal cord compression, and/or progressive growth. Participants with a history of CNS metastases or spinal cord compression may be enrolled if they have received definitive treatment and are considered clinically stable by the investigator after discontinuation of anticonvulsants and for 8 weeks prior to initiation of study treatment. Participants with untreated, asymptomatic brain metastases (i.e., no neurological symptoms, no requirement for corticosteroids, no brain metastatic lesion with a longest diameter > 1.5 cm, and no significant edema peripheral to brain metastatic lesions) may be enrolled. Brain metastatic lesions will not be designated as target lesions.
  14. Participants with current or prior disease requiring systemic therapy (including, but not limited to, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, rheumatoid arthritis, scleroderma, multiple sclerosis, hemolytic anemia, Sjögren's syndrome, and sarcoidosis).
  15. Current requirement for systemic corticosteroids or use of systemic corticosteroids within 4 weeks prior to enrollment (inhaled corticosteroids are permitted for participants with asthma or , as are other non-systemic steroids such as topically administered corticosteroids).
  16. In the investigator's judgment, the participant has other serious illnesses that make participation in this study inappropriate.
  17. Participant is unwilling or unable to follow protocol requirements.
  18. Other primary within 3 years prior to enrollment that has not been treated with curative intent (the investigator may consider discussion with the Medical Monitor), excluding non-metastatic basal cell/squamous cell carcinoma of the skin or non-muscle-invasive bladder cancer.
  19. Any condition that, in the investigator's judgment, may interfere with the evaluation of the drug, participant safety, or interpretation of study results.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    Phase Ia:Dose Escalation and Backfill

    HLX316 dose levels of 1, 3, 10, 20, and 30 mg/kg, QW. Participants will be assigned to one of the dose cohorts according to the study schedule.

    Drug: HLX316

  • Experimental
    Phase Ib:Dose Expansion

    The SRC will recommend dose cohorts for Phase Ib dose expansion based on the safety, efficacy, and PK data from Phase Ia; the tentative dose expansion cohorts are HLX316 10.0 mg/kg and 20 mg/kg administered as intravenous infusion QW.

    Drug: HLX316

Interventions

  • DrugHLX316

    Participants will receive HLX316 administered by intravenous infusion on D 1 of each cycle, with a cycle length of 1 week.

06

What researchers measure

Primary outcomes

  1. The proportion of participants within each dose cohort who experience dose-limiting toxicity (DLT) events during the DLT evaluation period

    Time frame: 21 days

  2. To determine the maximum tolerated dose (MTD) of HLX316

    Time frame: 18 months

  3. RP2D

    The recommended phase 2 dose of HLX316

    Time frame: 24 months

  4. Objective response rate (ORR)

    Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment.

    Time frame: 6 months

Secondary outcomes

  1. AE

    The types and frequencies of adverse events (AEs) evaluated according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 6.0

    Time frame: 24 months

  2. PK

    maximum concentration (Cmax)

    Time frame: 24 months

  3. PK

    time to maximum concentration (Tmax)

    Time frame: 24 months

  4. PK

    elimination half-life (t1/2)

    Time frame: 24 months

  5. PK

    area under the concentration-time curve (AUC)

    Time frame: 24 months

  6. PK

    volume of distribution (Vz)

    Time frame: 24 months

  7. PK

    ,clearance (CL), and accumulation ratio (Rac)

    Time frame: 24 months

  8. Duration of response (DOR)

    DOR is defined as the time from first evidence of response (CR or PR per RECIST 1.1) to earlier date of disease progression or death due to any cause

    Time frame: 24 months

  9. Progression-free survival (PFS)

    The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause,whichever occurred first.

    Time frame: 24 months

  10. Overall survival (OS)

    Time from the date of enrollment to the date of death for any cause.

    Time frame: 24 months

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 21, 2026
StartActual
May 22, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jun 1, 2029
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07541534
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 22, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
May 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion